Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
RIGEL PHARMACEUTICALS INC
Bear Case (25th pct.)
58.8% vs price
Base Case (Median)
73.8% vs price
Bull Case (75th pct.)
78.6% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| Graham Number | $89.58 | 83.3% | Medium (40%) |
| EV/EBITDA | $70.26 | 43.8% | Medium (20%) |
| EV/FCF | $84.94 | 73.8% | Medium (20%) |
Based on 3 out of 7 methods, RIGL appears undervalued at the current price of $48.86. The base case fair value of $84.94 implies 73.8% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.